Human Immunodeficiency Virus Type 1 (HIV-1), Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) are viruses transmitted by exposure to contaminated blood, plasma products, certain body tissues, bodily fluids, by sexual contact, or by an infected mother to the newborn child. According to the World Health Organization (WHO), there are approximately 38 million people living with HIV/AIDS in the world. Hepatitis C virus (HCV) and hepatitis B virus (HBV) affect 71 million and 257 million people worldwide respectively. Although serological screening assays have been used to screen for these viruses using an individual’s donated blood to reduce transmission risk, a nucleic acid base molecular diagnostic test could further assist in reducing the risk of transmission from blood donations.

The Atila Blood Screening Assay Kit is a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay based on a proprietary technology developed to improve the efficiency of detecting multiple viral nucleic acid targets simultaneously (HIV-1, HBV and HCV) with superior specificity.